HMHannah Jane Maple

Hannah Jane Maple

*This is an algorithmically generated author record based on publicly available information.

Hannah Jane Maple has a total of 218 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Structure-Guided Design of ISOX-DUAL-Based Degraders Targeting BRD4 and CBP/EP300: A Case of Degrader Collapse

    by Anthony K. Edmonds, Dimitrios-Ilias Balourdas, Graham P. Marsh, Robert Felix, Bradley Brasher, Jeff Cooper, Cari Graber-Feesl, Madhu Kollareddy, Karim Malik, Helen Stewart, et al.

    Degraders with dual activity against BRD4 and CBP/EP300 were designed. A structure-guided design approach was taken to assess and test potential exit vectors on the dual BRD4 and CBP/EP300 inhibitor, ISOX-DUAL. Candidate degrader panels revealed that VHL-recruiting moieties could mediate dose-responsive ubiquitination of BRD4. A panel of CRBN-recruiting thalidomide-based degraders was unable to induce ubiquitination or degradation of target proteins. High-resolution protein cocrystal structures revealed an unexpected interaction between the thalidomide moiety and Trp81 on the first bromodomain of BRD4. The inability to form a ternary complex provides a potential rationale for the lack of degrader activity with these compounds, some of which have remarkable affinities close to those of (+)-JQ1, as low as 65 nM in a biochemical assay, vs 1.5 μM for their POI ligand, ISOX-DUAL. Such a "degrader collapse" may represent an under-reported mechanism by which some putative degrader molecules are inactive with respect to target protein degradation.


  • Open Access

    BromoCatch: a self-labelling tag platform for protein analysis and live cell imaging

    by Maria Rodriguez-Rios, Conner G. Craigon, Mark A. Nakasone, Adam G. Bond, Mark Dorward, Anthony K. Edmonds, Mark C. Norley, Robert E. Arnold, Paul M. Wood, Stephen J. Reynolds, et al.

    Visualizing and manipulating proteins in live cells is crucial for studying complex biological processes. Self-labelling protein (SLP) tags such as HaloTag and SNAP-tag can be fused to genes of interest to allow protein labelling in cells. Limitations including size of the tag and suboptimal fitness of reactivity motivate development of improved tools to enable rapid, specific and stable protein labelling. We present BromoCatch, a novel SLP platform based on a small ∼13 kDa bromodomain (BD) engineered with a nucleophilic cysteine for covalent ligand engagement. A structure-based designed library of 16 “bumped” binders bearing diverse electrophilic warheads was screened against two different cysteine mutants using differential scanning fluorimetry and intact protein mass spectrometry to monitor covalent complex formation. The para-acrylamide bumped derivative MR116 and the Brd4-BD2 double mutant L387A,E438C formed the most potent and stable adduct, and its binding mode through covalent modification was confirmed by an X-ray cocrystal structure solved to 1.3 Å of resolution. BromoCatch exhibited potent and irreversible target engagement in cells through nanoBRET and residence time assays. Practicality and scope are further demonstrated through the design and proof-of-concept application of a biotinylated conjugate, PROTAC tag degraders, and fluorescent probes of both full-on and switch-on types for ex-cellulo and live-cell imaging. Together, we qualify BromoCatch as a novel, versatile and efficient protein labelling tool and technology platform. Its advantageous design features and kinetic fitness, and its modular design enabling diverse functionalities, are anticipated to usher a range of future applications and witness broad utility.


  • Open Access

    Discovery of a CNS active GSK3 degrader using orthogonally reactive linker screening

    by Andreas Holmqvist, Nur Mehpare Kocaturk, Christina Duncan, Jennifer Riley, Steve Baginski, Graham Marsh, Joel Cresser-Brown, Hannah Maple, Kristiina Juvonen, Nicola Morrice, et al.

    Bifunctional targeted protein degraders, also known as Proteolysis Targeting Chimeras (PROTACs), are an emerging drug modality that may offer a new approach to understand and treat neurodegenerative diseases. These molecules have a non-occupancy based, sub-stoichiometric mechanism of action which results in removal of target proteins from cells, presenting new opportunities to interrogate and intervene in pathogenic signalling. Identifying chemical starting points for PROTACs remains a largely empirical process and the design rules for identifying in vivo quality tools to interrogate new therapeutic hypotheses in the Central Nervous System (CNS) have yet to be established. We demonstrate a concept of using orthogonally reactive linker reagents, that allowed us to construct screening libraries varying the E3 ligase recruiting ligand, the target protein recruiting ligand and the linker simultaneously and test compounds directly in cells. This led us identify a molecule directly from our screen that upon further profiling demonstrated rapid and selective Glycogen Synthase Kinase 3 (GSK3) degradation in cells, as well as CNS in vivo activity in mouse. Our findings provide new opportunities to investigate the role of GSK3 paralogs in cellular and in vivo disease models and demonstrate a successful Direct-to-Biology approach, with broad potential for identifying in vivo quality bifunctional chemical probes for CNS disease concepts.


  • Open Access

    Development of p300-targeting degraders with enhanced selectivity and onset of degradation

    by Graham P. Marsh, Mark S. Cooper, Sean Goggins, Stephen J. Reynolds, Dean F. Wheeler, Joel O. Cresser-Brown, Robert E. Arnold, Emily G. Babcock, Gareth Hughes, Darko Bosnakovski, et al.

    P300 and CBP are paralogous epigenetic regulators and promising therapeutic targets for which TPD offers the potential to achieve paralog-selective degradation.


  • Open Access

    Structure-guided design of ISOX-DUAL-based Degraders targeting BRD4 and CBP/EP300. A case of Degrader collapse

    by Anthony Edmonds, Dimitrios-Ilias Balourdas, Graham Marsh, Robert Felix, Bradley Basher, Jeff Cooper, Cari Grabl-Feesl, Madhu Kollareddy, Karim Malik, Helen Stewart, et al.

    Degraders with dual activity against BRD4 and CBP/EP300 were designed. A structure-guided design approach was taken to assess and test potential exit vectors on the dual BRD4 and CBP/EP300 inhibitor, ISOX-DUAL. Candidate Degrader panels revealed that VHL-recruiting moieties could mediate dose-responsive ubiquitination of BRD4. A panel of CRBN-recruiting thalidomide-based Degraders were unable to induce ubiquitination or degradation of target proteins. High-resolution protein co-crystal structures revealed an unexpected interaction between the thalidomide moiety and Trp81 on the first bromodomain of BRD4. The inability to form a ternary complex provides a potential rationale for the lack of Degrader activity with these compounds, some of which have remarkable affinities close to those of (+)-JQ1, as low as 65 nM in a biochemical assay, vs 1.5 M for their POI ligand, ISOX-DUAL. Such a “Degrader collapse” may represent an under-reported mechanism by which some putative Degrader molecules are inactive with respect to target protein degradation.

  • Open Access

    Structure-Based Optimization of Pyridone α-Ketoamides as Inhibitors of the SARS-CoV-2 Main Protease

    by Ravi Kumar Akula, Haifa El Kilani, Alina Metzen, Judith Röske, Kaixuan Zhang, Matthias Göhl, Nanaji Arisetti, Graham P. Marsh, Hannah J. Maple, Mark S. Cooper, et al.

    The main protease Mpro is a clinically validated target to treat infections by the coronavirus SARS-CoV-2. Among the first reported Mpro inhibitors was the peptidomimetic α-ketoamide 13b, whose cocrystal structure with Mpro paved the way for multiple lead-finding studies. We established structure-activity relationships for the 13b series by modifying residues at the P1', P3, and P4 sites. Guided by cocrystal structures, we reduced the P1' substituent size to better fill the pocket and added a fluorine substituent to the pyridone ring, enabling a new hydrogen bond with Gln189 in P3. Among 22 novel analogues, 6d and 12d inhibited Mpro with IC50s of 110 nM and 40 nM, improving the potency of 13b by up to 9.5-fold. Compound 6d had pronounced antiviral activity with an EC50 of 1.6 μM and was stable in plasma and microsomes. The study illustrates the potential of structure-based design to systematically improve peptidomimetic α-ketoamides.


  • Evaluation of Cereblon-Directing Warheads for the Development of Orally Bioavailable PROTACs

    by Marisa Actis, Joel Cresser-Brown, Elizabeth A. Caine, Martin Steger, Anup Aggarwal, Anand Mayasundari, Nancy Murphy, Gintvile Valinciute, Yong Li, Xiang Fu, et al.

    PROTACs usually occupy physicochemical space outside the one defined by classical drug-like molecules, which often presents considerable challenges in their optimization and development for oral administration. We have previously reported phenyl glutarimide (PG)-based BET PROTAC SJ995973, with improved overall in vitro degradation and antiproliferative activities compared to its direct thalidomide-based analogue dBET1, but similarly poor in vivo pharmacokinetic profile. To further demonstrate the PG utility, we describe here optimization efforts that led to the discovery of an orally bioavailable BET-PROTAC SJ44236 (8), and results of a comprehensive in vitro/vivo comparative study with analogues containing alternative CRBN-directing warheads. Our study highlights the importance of considering warhead modifications when optimizing PROTACs for oral delivery.


  • Efficient, multi-hundred-gram scale access to E3 ubiquitin ligase ligands for degrader development

    by Mark S. Cooper, Mark C. Norley, Simon Armitage, Joel O. Cresser-Brown, Anthony K. Edmonds, Sean Goggins, Jonathan P. Hopewell, Burhan Karadogan, Kevin A. Knights, Toby J. Nash, et al.

    Supporting degrader discovery programs in scale and scope: facile access to multi-hundred-gram quantities of the common E3 ligase ligands.


  • Open Access

    Chirality: a key parameter in chemical probes

    by Andrew McGown, Jordan Nafie, Mohammed Otayfah, Storm Hassell-Hart, Graham J. Tizzard, Simon J. Coles, Rebecca Banks, Graham P. Marsh, Hannah J. Maple, George E. Kostakis, et al.

    Many small molecule bioactive and marketed drugs are chiral. They are often synthesised from commercially available chiral building blocks. However, chirality is sometimes incorrectly assigned by manufacturers with consequences for the end user ranging from: experimental irreproducibility, wasted time on synthesising the wrong product and reanalysis, to the added cost of purchasing the precursor and resynthesis of the correct stereoisomer. Further on, this could lead to loss of reputation, loss of funding, to safety and ethical concerns due to potential in vivo administration of the wrong form of a drug. It is our firm belief that more stringent control of chirality be provided by the supplier and, if needed, requested by the end user, to minimise the potential issues mentioned above. Certification of chirality would bring much needed confidence in chemical structure assignment and could be provided by a variety of techniques, from polarimetry, chiral HPLC, using known chiral standards, vibrational circular dichroism, and x-ray crystallography. A few case studies of our brushes with wrong chirality assignment are shown as well as some examples of what we believe to be good practice.


  • Developing, Choosing, and Using the Chemical Toolbox for Infectious Diseases Research

    by Alex Moloney, Hannah J. Maple

    Scientific progress is built on "what went before". As research in a field or discipline progresses, laying strong and scientifically correct foundations for each incremental discovery ultimately accelerates progress. The importance of "research tools" (e.g., chemical probes, antibodies, assays) that underpin researchers' efforts to probe and understand biological systems and pathways should therefore not be underestimated. Appropriate validation, protocol development, and ultimately availability of research tools are critical, in parallel with education on the appropriate selection and use of these tools.